bluebird bio (NASDAQ: BLUE) reported Q1 EPS of ($0.76), $0.15 worse than the analyst estimate of ($0.61). Revenue for the quarter came in at $6.3 million versus the consensus estimate of $6.2 million.

For earnings history and earnings-related data on bluebird bio (BLUE) click here.